U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H30O4
Molecular Weight 370.4819
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SEGESTERONE ACETATE

SMILES

CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C

InChI

InChIKey=CKFBRGLGTWAVLG-GOMYTPFNSA-N
InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1

HIDE SMILES / InChI
Molecular Formula C23H30O4
Molecular Weight 370.4819
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Segesterone acetate (elcometrine), a progestin, is sold in combination with ethinyl estradiol under the brand name Annovera. Annovera is indicated for use by females of reproductive potential to prevent pregnancy. Segesterone acetate acts as an agonist of the progesterone receptor and it doesn’t possess estrogenic, androgenic, antiandrogenic, or antimineralocorticoid activity.

Originator

Approval Year

2018
425
Targets

Targets

Primary TargetPharmacologyConditionPotency
Progesterone receptor
61
Target ID: P06401
Gene ID: 5241.0
Gene Symbol: PGR
Target Organism: Homo sapiens (Human)
Agonist
2752
 56.0 nM [EC50]
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Preventing
Phase III
665
ELMETRIN

Approved Use

Unknown
Preventing
Approved
8583
ANNOVERA

Approved Use

is indicated for use by females of reproductive potential to prevent pregnancy

Launch Date

2018
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
942.9 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/29409834/
200 μg 1 times / day steady-state, vaginal
dose: 200 μg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ESTRADIOL
ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
1147 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
294 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
875 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6509989/
22 mg single, vaginal
dose: 22 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SEGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
0.423 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8131396/
100 μg single, oral
dose: 100 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
SEGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
38685.7 pg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/29409834/
200 μg 1 times / day steady-state, vaginal
dose: 200 μg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ESTRADIOL
ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
15 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
3.9 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
323 nM × min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8131396/
100 μg single, intravenous
dose: 100 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SEGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
26 nM × min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8131396/
100 μg single, oral
dose: 100 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
SEGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
4.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
11.25 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6509989/
22 mg single, vaginal
dose: 22 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SEGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
158 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8131396/
100 μg single, intravenous
dose: 100 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SEGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
60 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8131396/
100 μg single, oral
dose: 100 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
SEGESTERONE ACETATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
13%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2272183/
SEGESTERONE ACETATE serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Disc. AE: Menometrorrhagia, Migraine headache...
Other AEs: Migraine headache, Nausea and vomiting...
AEs leading to
discontinuation/dose reduction:
Menometrorrhagia (1.7%)
Migraine headache (1.3%)
Vulvovaginal mycotic infection (1.3%)
Nausea and vomiting (1.2%)
Uterine myoma expulsion (1.4%)
Other AEs:
Migraine headache (38.6%)
Nausea and vomiting (25%)
Vulvovaginal mycotic infection (14.5%)
Abdominal pain lower (13.3%)
Dysmenorrhea (12.5%)
Vaginal discharge (11.8%)
Genitourinary tract infection (10%)
Breast discomfort (9.5%)
Disorder menstrual (7.5%)
Diarrhea (7.2%)
Pruritus genital (5.5%)
Thrombosis NOS (>= 2 patients)
Psychiatric disorder NOS (>= 2 patients)
Drug hypersensitivity (>= 2 patients)
Abortions spontaneous (>= 2 patients)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Nausea and vomiting 1.2%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Migraine headache 1.3%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Vulvovaginal mycotic infection 1.3%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Uterine myoma expulsion 1.4%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Menometrorrhagia 1.7%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Genitourinary tract infection 10%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Vaginal discharge 11.8%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Dysmenorrhea 12.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Abdominal pain lower 13.3%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Vulvovaginal mycotic infection 14.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Nausea and vomiting 25%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Migraine headache 38.6%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Pruritus genital 5.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Diarrhea 7.2%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Disorder menstrual 7.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Breast discomfort 9.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Abortions spontaneous >= 2 patients
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Drug hypersensitivity >= 2 patients
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Psychiatric disorder NOS >= 2 patients
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Thrombosis NOS >= 2 patients
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
healthy, 18 - 40 years
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252

inducer
1087
inhibitor
2438

inducer
440
inhibitor
2507

inducer
109
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2A6
879

CYP2B6
926

CYP2C8
1057

CYP2C19
2057

CYP2E1
1060
CYP1A2
832

CYP2B6
669

CYP2C19
329

CYP3A5
92
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 unlikely
CYP1A2
2333
 unlikely
CYP2A6
911
 unlikely
CYP2B6
1160
 unlikely
CYP2B6
1160
 unlikely
CYP2C19
2141
 unlikely
CYP2C19
2141
 unlikely
CYP2C8
1117
 unlikely
CYP2C9
2497
 unlikely
CYP2C9
2497
 unlikely
CYP2D6
2546
 unlikely
CYP2D6
2546
 unlikely
CYP2E1
1146
 unlikely
CYP3A4
2633
 unlikely
CYP3A4
2633
 unlikely
CYP3A5
201
 unlikely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEMBL
CHEMBL2107778
ChemIDplus
7690086
https://chem.nlm.nih.gov/chemidplus/id/0007690086
Compound Cloud
11823650
DrugBank
DB14584
https://www.drugbank.ca/drugs/DB14584
EPA DSSTox
DTXSID00998190
https://comptox.epa.gov/dashboard/DTXSID00998190
KEGG
D10987
http://www.genome.jp/dbget-bin/www_bget?dr:D10987
SureChEMBL
SCHEMBL7053392
https://www.surechembl.org/chemical/SCHEMBL7053392
Wikidata
Q24882947
ZINC
ZINC000033964021
http://zinc15.docking.org/substances/ZINC000033964021
PubMed

PubMed

TitleDatePubMed
Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat.
2010-10-26
Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
2007-06
Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses.
2003-02
Nestorone: a progestin with a unique pharmacological profile.
2000-12-08
Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women.
1999-02
Patents

Patents

US 3262950
2

Sample Use Guides

In Vivo Use Guide
Elcometrine is delivered within a single subdermal capsule of medical grade polydimethylsiloxane, containing 50 mg of elcometrine. In clinical trials, administration by a vaginal ring was investigated (150 mg of Nestorone and 15 mg of ethinyl estradiol). The development of transdermal gel containing elcometrine is also reported.
Route of Administration: Other
In Vitro Use Guide
Female Sprague–Dawley rats were ovariectomized and 1 week later, injected daily for 3 days with 1 mg 17 b-estradiol (E2) to induce synthesis of PR. The animals were killed on day 4, uteri were collected over dry ice and homogenized. Aliquot of cytosol were incubated overnight at 4°C in glass tubes with [3H]promegestone with or without cold nestorone at different concentrations. The bound and free radioactivity was separated by the dextran-charcoal method.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:52:24 GMT 2025
Edited
by admin
on Mon Mar 31 17:52:24 GMT 2025
Record UNII
9AMX4Q13CC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SEGESTERONE ACETATE
USAN  
USAN  
Official Name English
ELCOMETRINE
MI  
Preferred Name English
16-METHYLENE-17.ALPHA.-ACETOXY-19-NOR-PREGN-4-ENE-3,20-DIONE
Common Name English
19-NORPREGN-4-ENE-3,20-DIONE, 17-(ACETYLOXY)-16-METHYLENE-
Common Name English
ANNOVERA COMPONENT SEGESTERONE ACETATE
Brand Name English
Segesterone acetate [WHO-DD]
Common Name English
ELCOMETRINE [MI]
Common Name English
17-(ACETYOXY)-16- METHYLENE -19-NONPREGN-4-ENE-3,20-DIONE
Common Name English
ST-1435
Code English
NESTORONE
Brand Name English
SEGESTERONE ACETATE [ORANGE BOOK]
Common Name English
SEGESTERONE ACETATE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C776
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C152316
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
DRUG BANK
DB14583
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
USAN
DE-09
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
WIKIPEDIA
Segesterone acetate
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
FDA UNII
9AMX4Q13CC
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
ChEMBL
CHEMBL3707377
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
MERCK INDEX
m4856
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY Merck Index
RXCUI
2055977
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
CAS
7759-35-5
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
DAILYMED
9AMX4Q13CC
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
EPA CompTox
DTXSID70998804
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
PUBCHEM
108059
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
DRUG CENTRAL
3175
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
SMS_ID
300000034700
Created by admin on Mon Mar 31 17:52:24 GMT 2025 , Edited by admin on Mon Mar 31 17:52:24 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
GLUCOCORTICOID RECEPTOR
TARGET -> AGONIST
EC50
PROGESTERONE RECEPTOR
TARGET -> AGONIST
EC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Structure of GESTADIENOL ACETATE
TARGET->ANALOGUE
Related Record Type Details
Structure of 5.ALPHA.-DIHYDROSEGESTERONE ACETATE
METABOLITE -> PARENT
Structure of ((8R,9R,10S,13S,14S,17R)-17-(1-HYDROXYETHYL)-13-METHYL-16-METHYLENE-3-OXO-2,4,5,6,7,8,9,10,11,12,14,15-DODECAHYDRO-1H-CYCLOPENTA(A)PHENANTHREN-17-YL) ACETATE
METABOLITE INACTIVE -> PARENT
Structure of 3ALPHA, 5ALPHA-TETRAHYDROSEGESTERONE ACETATE
METABOLITE INACTIVE -> PARENT
Structure of 4, 5-DIHYDRO-17.ALPHA.-DEACETYLSEGESTERONE ACETATE
METABOLITE -> PARENT
Structure of 3BETA, 5ALPHA-TETRAHYDROSEGESTERONE ACETATE
METABOLITE -> PARENT
Related Record Type Details
Structure of SEGESTERONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966